glp 1 agonisté GLP-1 Receptor Agonists: The New Wave in Diabetes Management The Unstoppable Rise of GLP-1
Description
Klebanoff: Medicaid programs are not required to cover drugs for weight loss, even if FDA-approved
A lot of people are using it for cosmetic purposes
FMD, Flow-Mediated Dilatation
Although considerably smaller than the 34000Da peptide drugs, these small molecules are still around 700Da molecular weight further adding to computational modelling complexity
In intact murine islets, blockade of N-type Ca 2+ channels with -conotoxin, but not L-type Ca 2+ channels using nifedipine, abolishes low glucose (1 mM) stimulation of glucagon secretion and blunts the GLP-1-mediated inhibitor effects
